Abstract
Patients might experience severe adverse reactions during anti-tumor therapy, which seriously affect the quality of life and need to be closely monitored. Chemotherapy with platinum-based drugs, taxanes and other cytotoxic agents may trigger extremely rare and severe nerve damage, potentially leading to the serious consequence of paralysis. Bevacizumab, when administered in combination with chemotherapy agents, may exacerbate neurotoxicity, potentially leading to paralysis. In this case report, a patient with lung adenocarcinoma experienced peripheral paresthesia affecting hands and feet after initial treatment with paclitaxel, nedaplatin, and sintilimab, and rapid progression to paralysis due to neurotoxic effects after switching to bevacizumab combined with osimertinib. While standard therapies for severe paralysis typically fail to yield significant functional improvements, this patient experienced marked symptom relief after acupuncture, together with demonstrable down-regulation of systemic inflammation and immunosuppression. This case report indicates the need for clinical caution when using bevacizumab to avoid exacerbating chemotherapy's adverse effects. Additionally, acupuncture may serve as a complementary approach for mitigating severe adverse events experienced by cancer patients, and changes in peripheral lymphocyte subsets (e.g., CD4+/CD8 + T-cell ratios) may be closely associated with efficacy and prognosis.
Introduction
Anti-tumor therapies—particularly combinations involving platinum-based drugs, taxanes, and targeted agents like bevacizumab—can occasionally trigger severe neurotoxicity. In extreme cases, this manifests as complete paralysis, a devastating adverse effect that drastically reduces a patient's quality of life and complicates further cancer treatment.
Standard symptomatic treatments, such as glucocorticoids and neuroprotective agents, often fail to yield significant functional improvements for this level of nerve damage. This case study explores the management of severe, treatment-resistant neurotoxicity, specifically investigating the potential of acupuncture to restore motor function and modulate the underlying neuro-inflammatory and immunosuppressive state of the patient.
Methods
This retrospective study focuses on a 63-year-old woman with stage IV lung adenocarcinoma. After developing Grade 4 paralysis following treatment with bevacizumab and osimertinib, and failing to improve with standard symptomatic care, she underwent an intensive acupuncture regimen.
- Acupuncture Protocol: The patient received acupuncture 5–6 times a week for 4 weeks. Specific traditional acupoints were targeted (e.g., CV17, ST36, BL23). Needles were inserted 1.5–2.5 cm deep and manipulated manually to achieve the sensation of De Qi, then left in place for 30 minutes.
- Monitoring: Clinical outcomes were tracked using the Visual Analogue Scale (VAS) for pain, standard Muscle Strength Grading, and the Karnofsky Performance Status (KPS) scale. Peripheral blood markers, specifically cytokines and lymphocyte subsets, were measured before and after the 4-week treatment.
Key Results and Insights
Clinical Recovery
Within 4 weeks of starting acupuncture, the patient progressed from complete paralysis (Muscle Strength Grade 0) to walking slowly unaided. Muscle pain dropped from a VAS score of 4 to 0. The patient's KPS improved from 60 (requiring occasional assistance) to 80 (normal activity with effort) at discharge, eventually reaching 90 at follow-up. The paralysis did not recur over a nearly two-year follow-up period.
Cytokine Balancing Act
High levels of IL-6 (pro-inflammatory) and IL-10 (anti-inflammatory/immunosuppressive) are linked to neuro-inflammation and poor prognosis. Post-acupuncture, both cytokines dropped significantly, suggesting a restoration of the inflammatory balance necessary for nerve healing. IL-6 levels dropped from 11.60 pg/ml to 5.13 pg/ml, returning to the normal range, while IL-10 plummeted from 18.80 pg/ml to 1.60 pg/ml.
T-Cell Reactivation and Immune Modulation
Before treatment, the patient exhibited an immunosuppressed state with low counts of crucial memory and effector T cells. After acupuncture, absolute counts of CD3+ T cells more than doubled (811 to 1738 /µL). CD4+ T cells increased from 364 to 716 /µL, and CD8+ T cells from 366 to 819 /µL. This rebound suggests the treatment may help convert a "cold" tumor environment into a "hot" one, potentially enhancing the efficacy of subsequent cancer therapies.
Discussion and Limitations
The study suggests acupuncture might actively modulate the immune system, shifting the patient from an immunosuppressed state to a more active anti-tumor environment. The rapid onset of paralysis following the introduction of bevacizumab highlights a critical clinical warning: combining it with prior neurotoxic regimens (like paclitaxel) can severely exacerbate nerve damage.
As this is a single-patient case report, it is impossible to definitively prove causality between acupuncture and the observed clinical changes. Spontaneous recovery or delayed effects of prior treatments cannot be entirely ruled out. High-quality, large-scale clinical trials and mechanistic studies are required to substantiate these findings and understand how acupuncture triggers these changes in peripheral lymphocyte cells and cytokine levels.
Summary updated